INTRODUCTION
The microtubule-associated protein kinases (MAP-2 kinase, ERK-2 or p42MAPK) are serine/threonine kinases that are activated upon stimulation of cells with several agents such as insulin, growth factors, proto-oncogene products and phorbol esters [1] [2] [3] . Several isoforms of MAPK have been described in different systems, although they are structurally related [4] . These enzymes phosphorylate other key kinases and proteins, and they play a central role in the signal-transduction mechanism that transduces mitogenic signals from an activated receptor kinase to the cell interior [3] . MAPKs themselves are regulated by phosphorylation. Activation of MAPKs requires the phosphorylation of both threonine and tyrosine residues [5] . The protein serine/threonine phosphatase-2A or the protein tyrosine phosphatase CD45 specifically inactivates MAPK activities [5, 6] . A MAPK kinase has been described in nerve-growth-factorstimulated pheochromocytoma (PC 12) cells that phosphorylates MAPK on serine/threonine and tyrosine [7] . Another member of the MAPK family has been shown to be phosphorylated and activated by the tyrosyl kinase p561ck that is related to src-protein tyrosine kinases [8] . Several MAPK substrates have been identified so far in several cell systems in vitro [9, 10] . They include: MAP2, ribosomal-protein S6 kinase (S6K), myelin basic protein (MBP), c-jun proto-oncogene product and c-Raf- 1 proteins. One of these MAPK substrates, S6K, is another serine/threonine kinase that in turn phosphorylates S6, a major component of the large 40 S ribosomal unit [11] . The S6K is encoded by rsk in mouse and chick fibroblasts and also by the raf gene [12] .
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor required for the proantibodies, follows similar time-and dose-response curves as the kinase activation. Pretreatment of the cells with the tyrosine kinase inhibitor genistein abrogates the above-mentioned effect, whereas the phosphatase inhibitor okadaic acid enhances both the basal and the GM-CSF-stimulated kinase activities. Likewise, MAPK tyrosine phosphorylation is diminished in genisteintreated neutrophils, and enhanced in okadaic acid-treated cells. We conclude that MAPK activity is present in human neutrophils, and that it is stimulated by GM-CSF. This stimulation of the activity is most likely due to the phosphorylation of MAPK in tyrosine residues triggered upon binding of GM-CSF to its receptors.
liferation of myelomonocytic stem cells in vivo and in vitro [13, 14] . GM-CSF also acts on mature neutrophils, potentiating their physiological functions. These include superoxide generation, platelet-activating factor and arachidonic acid release, phagocytosis and degranulation (reviewed in [15] ). The mechanism of this priming process is still unknown. Recently it has been found [16] [17] [18] [19] [20] [21] that incubation of human neutrophils with GM-CSF triggers a rapid phosphorylation of tyrosine residues of several proteins, including a protein of 41 kDa (p41).
The presence of tyrosine-specific protein kinase activities in human neutrophils has recently been demonstrated [22] [23] [24] . However, the roles of these kinases in neutrophil functions and the identities of their substrates remain largely unknown. Recently we have shown that the p41 protein, which is phosphorylated on tyrosine residues in neutrophils stimulated by various agonists, is a member of the MAPK family [25] . The present studies were undertaken to examine: (a) the presence of a MAPK activity in human neutrophils; (b) whether this activity is stimulated by the haematopoietic growth factor GM-CSF; and (c) whether a correlation exists between MAPK activation and its tyrosyl phosphorylation. Our data show that low MAPK activity can be measured in quiescent cells. This activity can be greatly enhanced in GM-CSF-stimulated neutrophils, and its stimulation correlates with the tyrosine phosphorylation of MAPK.
MATERIALS AND METHODS Materials GM-CSF was purchased from Amgen Biologicals (Thousand Oaks, CA, U.S.A.); Hepes, leupeptin, sodium orthovanadate, phenylmethanesulphonyl fluoride, cyclic-AMP-dependent pro-Biotechnology Inc. and used at a 1:1000 dilution (1 /zg/ml final concn. in Western blots). MK12 monoclonal, IgG1 antibody to MAP kinase (anti-MAPK) was purchased from Zymed Laboratories Inc. (South San Francisco, CA, U.S.A.) and used at a dilution of 1:4000 (0.4 ,ug/ml final concn. in Western blots). MK12 is an anti-peptide antibody raised to the sequence TDEPVAEEPFTFDMELDDLPK, corresponding to amino acids 325-345 near the C-terminus of ERK-1 [26] .
Isolation of human neutrophils
Human neutrophils were isolated on Ficoll/Hypaque gradients by the method of English and Anderson [27] . The cells were resuspended in modified Hanks' Balanced Salt Solution containing 10 mM Hepes (pH 7.4), 124 mM NaCl, 4.9 mM KCI, 0.64 mM Na2HPO4, 0.66 mM KH2PO4, 15.2 mM NaHCO3, 0.1 % dextrose and 0.1 % BSA.
Cell lysis
Neutrophils (1 x 107 cells/ml) were incubated with the appropriate agents and lysed by addition of 1 vol. of lysis buffer (10 gM sodium orthovanadate, 10 mMp-nitrophenyl phosphate, 5.5 % Triton X-100, 1 mM DFP, 1 mM benzamidine, 2 jug/ml aprotinin, 0.7 ,ug/ml pepstatin A) to 10 vol. of the cell suspension for 10 
MAPK assay
The enzymic activity in whole lysates and in the purified DEAEcolumn fractions was measured as described [28, 29] with some modifications. Briefly, the required substrate peptide was diluted in freshly prepared kinase buffer (13.4 
Western blotting
This was performed as described previously [16] [17] [18] . Briefly, whole-cell lysates (60-100 ,ul) from control and stimulated neutrophils were mixed with 50,1 of Laemmli [30] were run with each gel along with the samples. The proteins were then transferred to PVDF sheets (Millipore Corp.) and the blots were treated with the appropriate antibodies. Western blots were developed by the ECL method for detection. Briefly, blots were blocked in Tris-buffered saline/Tween-20 (TBS-T) (20 mM Tris base, pH 7.6, 137 mM NaCl, 0.1 % Tween-20) supplemented with 5 % BSA, followed by incubation with the primary antibody in TBS-T and finally with horseradish-peroxidase-conjugated anti-mouse IgG at 1: 7000 dilution for 1 h at room temperature. Blots were autoradiographed for variable lengths of time (15 s-I min) with Kodak X-Omat film. When needed, protein bands were quantified by laser scanning densitometry (LKB Ultroscan; Pharmacia).
Blot stripping and re-probing When a Western-blotting procedure was completed and X-ray films were obtained, blots were stripped of the primaryantibody-secondary-antibody complex by incubating them in stripping buffer (100 mM fl-mercaptoethanol, 2 % SDS, 62.5 mM Tris/HCl, pH 6.7) for 30 min at 50 'C. Blots were then subjected to autoradiography for confirmation that the antibody signal had been removed. After this procedure, the blots were blocked with buffer containing 5 % BSA, and re-probed with a different antibody, in accordance with the procedure indicated above. substrate the MAPK substrate peptide (APRTPGGRR) that bears the Thr-97 phosphorylation site for MBP. As shown in Figure 1(a) , the maximal MAPK activity is up to 3-fold higher in lysates prepared from GM-CSF-stimulated cells than in control lysates prepared from unstimulated cells. The increase in MAPK activity was seen after 3 min incubation with GM-CSF, reaching a maximum between 5 and 10 min and then decreasing at 15 min (Figure la) . A similar time course was obtained when the phosphoacceptor substrate was MBP (results not shown). With this substrate, the maximum activation was 170 % of control (at 5 min after addition of GM-CSF). This value is somewhat lower than that obtained with the MAPK substrate peptide. As shown in Figure l(b) , the time course of GM-CSF-induced MAPK activation is similar to that of tyrosine phosphorylation of MAPK (which we have previously shown to be p41, a phosphoprotein of 41 kDa [25] ). Maximum phosphorylation levels can also be seen at 5-10 min. Both MAPK tyrosine phosphorylation and MAPK activity start to decline 15 min after GM-CSF addition (Figures la and lb) .
RESULTS

Measurement
The stimulation of MAPK activity by GM-CSF is dosedependent (Figure 2a) . With either of the aforementioned substrates, saturation of MAPK activity occurs at concentrations higher than 0.5-1 nM GM-CSF. The dose-response of GM-CSF-induced MAPK activation parallels that of MAPK tyrosine phosphorylation (Figure 2b ). In addition to GM-CSF, other known neutrophil stimulants are able to increase both the basal level of MAPK activity in the kinase assay in vitro and the phosphorylation of p41 in Western blots (Table 1) . Those (Figures 3a and b) . The effect was dose-dependent, with 100 ug/ml genistein producing maximum inhibition (results not shown). We next examined the effect of the protein phosphatase inhibitor okadaic acid. This compound is a potent inhibitor of serine/threonine-specific protein phosphatases 1 and 2A (PP1 and PP2A) and of phosphatase 2B at higher concentrations [32] . Figures 3(c) (Figure 4b ). Okadaic acid alone also increased the level of tyrosine phosphorylation of p41 (Figure 4d) lysates were obtained as indicated in the Materials and methods section. Lysates were diluted and loaded on to a DEAE-anion-exchange column in a Bio-Rad h.p.l.c. system. The column was washed with the equilibration buffer until protein readings returned to pre-loading basal levels (protein was monitored by measurement of A280, and it is not shown here for sake of clarity).
Elution was done with a linear gradient (----) from 0 to 0.4 M NaCI in the equilibration buffer at a flow rate of 1.0 ml/min; 0.5 ml fractions were collected every 30 s, and 20 ,1U of each was used to assay MAPK activity with the MAPK substrate peptide (0. from unstimulated cells assayed with MBP contained some basal MAPK activity (results not shown). With this substrate, a couple of peaks were found at elution times of 10 min and 12.5 min in a NaCl gradient from 0 to 0.4 M. This is in agreement with published data in other systems [33] and corresponds to the elution time of MAPK. Only the second peak (eluted at approx. 200 mM NaCl) shows an increased activity in fractions from GM-CSF-stimulated cells. Interestingly, 32P incorporation at the peak of maximum activity with GM-CSF is about 7 times (MAPK substrate peptide in the kinase assay) or 4 times (MBP) that found in the starting material (diluted lysates from GM-CSF-activated cells) loaded on to the column.
To confirm further the presence of the MAPK protein in our kinase assays, we loaded several eluate fractions from the DEAE column on to a SDS/PAGE gel; proteins were transferred to PVDF paper that was then probed with MK12 monoclonal antibody. As seen in Figure 6 (a), only those fractions that correspond to the peak of maximum activity have MAPKimmunoreactive protein, and a clear phosphorylation increase can be seen in protein p41 in fractions from GM-CSF-treated neutrophils (Figure 6b ).
DISCUSSION
The present data show that the activity of MAPK, as measured by the phosphorylation of myelin basic protein or the MAPK substrate peptide APRTPGGRR, in lysates prepared from unstimulated human neutrophils is very low. This activity is 215 greatly increased in lysates prepared from GM-CSF-treated cells (Figure la) . The stimulation is both time-and dose-dependent (Figures la and 2a) . The activation of MAPK by GM-CSF described herein is in agreement with results reported, while this manuscript was in preparation, in the human M07 cell line [34] and neutrophils and HL-60 cells [35] activated with haematopoietic growth factors, including GM-CSF. According to our data, both the time course and the dose-dependent curves of MAPK activation (Figures la and 2a) parallel those obtained from the GM-CSF-induced tyrosine phosphorylation of the 41 kDa protein (Figures lb and 2b) . Similarly, those neutrophil agonists that are able to elicit tyrosine phosphorylation of p41 are equally as capable of activating MAPK (the present paper). This p41 protein that becomes heavily phosphorylated on tyrosine upon cell stimulation has been shown to be MAPK [25, [34] [35] [36] . This conclusion was based on several biochemical and immunological approaches [25] , including molecularmass determination, subcellular localization and immunoprecipitation-immunoblotting experiments. A protein of similar molecular mass is known to be covalently modified in systems other than the neutrophils, such as the nicotinestimulated chromaffin cells and insulin-stimulated rat adipocytes [37, 38] . In addition to being phosphorylated on tyrosine, this protein is also phosphorylated on threonine residues [39, 40] .
Genistein, a specific protein tyrosine kinase inhibitor [41] , inhibited both the MAPK activity (Figures 3a and 3b ) and tyrosine phosphorylation of p41/MAPK (Figure 4b ). On the other hand, okadaic acid, a serine/threonine phosphatase inhibitor, stimulates MAPK activity (Figures 3c and 3d ) and p41/MAPK tyrosine phosphorylation (Figure 4d ). These results suggest that the inhibition of serine/threonine and tyrosine phosphatases is unmasking a large level of basal phosphorylation in a fashion similar to that described in other systems [42, 43] . This could take place probably at the level of the MAPK kinase, the enzyme upstream of the activation cascade that activates MAPK by phosphorylation. Results obtained with tyrosine kinase and protein phosphatase inhibitors, taken together, strongly suggest the presence of a tyrosine kinase/phosphatase mechanism in neutrophils involved in the elevation of MAPK activity by GM-CSF. This is in agreement with the previously reported data that MAPK activity is regulated by phosphorylation on both serine/threonine and tyrosine [39, 40] . Using lysates from neutrophils and DEAE-anion-exchange chromatography in a NaCl gradient, it was possible to localize the portion of the lysate that contains MAPK activity. A very sharp peak of MAPK activity was found after 12.5 min of elution with the NaCl gradient in fractions prepared from GM-CSF-treated cells ( Figure 5 ). The presence of MAPK kinase was determined by Western blotting using the antibody MK12 against MAPK ( Figure 6) . As 
